Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
Clinical Infectious Diseases (2021) - Comments
doi: 10.1093/cid/ciab845  issn: 1058-4838  issn: 1537-6591  pubmed: 34551104 

Fengcai Zhu, Pengfei Jin, Tao Zhu, Wenjuan Wang, Huayue Ye, Hongxing Pan, Lihua Hou, Jingxin Li, Xue Wang, Shipo Wu, Ying Wang, Jinbo Gou, Haitao Huang, Hongbin Wu, Xuewen Wang, Wei Chen